GSK (GSK) said Monday that it is partnering with the University of Oxford to investigate cancer prevention through vaccination, with GSK committing up to 50 million British pounds ($62.6 million) in funding over a minimum of three years.
The GSK-Oxford Cancer Immuno-Prevention program will focus on understanding precancer biology to uncover how cancer forms and identify potential vaccine strategies, the organizations said.
GSK's shares were up over 1% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。